Caj Haglund Selected Research

podocalyxin

10/2021	Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.
1/2020	Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas.
1/2015	Podocalyxin as a Prognostic Marker in Gastric Cancer.
1/2015	Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
7/2014	A comparative study of two PODXL antibodies in 840 colorectal cancer patients.
7/2014	Podocalyxin is a marker of poor prognosis in colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Caj Haglund Research Topics

Disease

146	Neoplasms (Cancer) 09/2022 - 01/2002
33	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 10/2002
28	Carcinogenesis 01/2022 - 02/2002
25	Adenocarcinoma 09/2022 - 06/2002
25	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2002
20	Stomach Neoplasms (Stomach Cancer) 06/2020 - 01/2003
16	Squamous Cell Carcinoma of Head and Neck 06/2022 - 12/2014
15	Pancreatic Neoplasms (Pancreatic Cancer) 09/2022 - 01/2004
12	Carcinoma (Carcinomatosis) 08/2019 - 06/2002
11	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2018 - 05/2003
10	Inflammation (Inflammations) 03/2022 - 01/2005
10	Breast Neoplasms (Breast Cancer) 06/2019 - 02/2002
9	Adenoma (Adenomas) 08/2019 - 04/2002
6	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 11/2003
6	Colonic Neoplasms (Colon Cancer) 01/2020 - 05/2008
6	Merkel Cell Carcinoma 04/2015 - 01/2004
5	Pheochromocytoma 01/2019 - 04/2003
5	Lung Injury 08/2008 - 06/2005
4	Oropharyngeal Neoplasms 01/2022 - 01/2018
4	Neuroendocrine Tumors (Neuroendocrine Tumor) 08/2019 - 08/2014
4	Lymphatic Metastasis 01/2016 - 01/2006
3	Neoplasms, Cystic, Mucinous, and Serous 01/2021 - 07/2009
3	Rectal Neoplasms (Rectal Cancer) 01/2020 - 01/2018
3	Paraganglioma (Paragangliomas) 01/2019 - 09/2016
3	Myoma 05/2016 - 04/2015
3	Thyroid Neoplasms (Thyroid Cancer) 01/2016 - 04/2013
3	Angiofibroma 05/2015 - 02/2011
3	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 08/2008 - 04/2006
3	Bronchopulmonary Dysplasia 08/2008 - 09/2003
2	Sialadenitis 10/2022 - 01/2020
2	Disease Progression 01/2022 - 01/2018
2	Cysts 01/2022 - 07/2004
2	Hypersensitivity (Allergy) 01/2022 - 08/2015
2	Residual Neoplasm 01/2022 - 10/2021
2	Ameloblastoma 01/2021 - 05/2019
2	Adenoid Cystic Carcinoma (Cylindroma) 01/2021 - 12/2017
2	Head and Neck Neoplasms (Head and Neck Cancer) 10/2020 - 04/2017

Drug/Important Bio-Agent (IBA)

44	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2002
32	Biomarkers (Surrogate Marker)IBA 09/2022 - 02/2005
18	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 09/2016 - 02/2002
15	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2022 - 01/2014
12	Matrix Metalloproteinases (MMPs)IBA 03/2022 - 01/2006
12	Tumor Biomarkers (Tumor Markers)IBA 01/2022 - 01/2004
12	Messenger RNA (mRNA)IBA 01/2019 - 06/2002
11	EnzymesIBA 03/2022 - 02/2006
10	Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric 06/2022 - 05/2002
10	DNA (Deoxyribonucleic Acid)IBA 08/2020 - 07/2008
8	ParaffinIBA 01/2021 - 01/2002
8	AntibodiesIBA 01/2019 - 02/2005
6	AntigensIBA 09/2022 - 05/2003
6	C-Reactive ProteinIBA 03/2022 - 11/2013
6	podocalyxinIBA 10/2021 - 07/2014
6	Kazal Pancreatic Trypsin InhibitorIBA 06/2021 - 07/2004
6	Polysaccharides (Glycans)IBA 01/2021 - 07/2009
6	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 09/2003
6	Blood Proteins (Serum Proteins)IBA 06/2020 - 08/2014
6	Carcinoembryonic AntigenIBA 06/2018 - 05/2002
6	Transcription Factors (Transcription Factor)IBA 01/2016 - 05/2008
6	Monoclonal AntibodiesIBA 07/2015 - 01/2002
6	TenascinIBA 07/2013 - 01/2003
5	Matrix Metalloproteinase 8 (Neutrophil Collagenase)IBA 03/2022 - 04/2017
5	Formaldehyde (Formol)FDA Link 01/2021 - 03/2005
5	ELAV-Like Protein 1IBA 09/2016 - 11/2003
5	Syndecan-1 (Syndecan 1)IBA 05/2013 - 01/2004
4	CarbohydratesIBA 09/2022 - 02/2009
4	CateninsIBA 01/2022 - 05/2014
4	TransketolaseIBA 01/2021 - 01/2016
4	Matrix Metalloproteinase 7 (Matrilysin)IBA 01/2021 - 06/2010
4	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2016
4	Serine Proteases (Serine Protease)IBA 06/2020 - 09/2003
4	Tissue Inhibitor of Metalloproteinase-1IBA 08/2019 - 07/2016
4	Estrogen ReceptorsIBA 06/2019 - 12/2007
4	Cyclin AIBA 07/2018 - 01/2004
4	Progesterone Receptors (Progesterone Receptor)IBA 05/2018 - 12/2007
4	TrypsinIBA 01/2012 - 09/2003
3	N-acetyltalosaminuronic acid (NAT)IBA 01/2022 - 01/2022
3	Trypsin InhibitorsIBA 01/2022 - 07/2004
3	CollagenIBA 05/2021 - 05/2013
3	beta CateninIBA 01/2021 - 05/2008
3	Deubiquitinating EnzymesIBA 01/2020 - 06/2017
3	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2020 - 06/2017
3	Small Interfering RNA (siRNA)IBA 01/2020 - 11/2003
3	Somatostatin Receptors (Somatostatin Receptor)IBA 08/2019 - 01/2019
3	Hormones (Hormone)IBA 05/2018 - 02/2002
3	Vascular Endothelial Growth Factor CIBA 08/2006 - 03/2005
3	Human beta Subunit Chorionic GonadotropinIBA 09/2004 - 10/2002
3	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 10/2003 - 02/2002
2	Immunoglobulin G (IgG)IBA 10/2022 - 01/2020
2	Cyclin D1IBA 01/2022 - 06/2019
2	Interleukin-6 (Interleukin 6)IBA 08/2021 - 10/2020
2	Cadherins (E-Cadherin)IBA 01/2021 - 01/2020
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2020 - 02/2006
2	Pharmaceutical PreparationsIBA 12/2020 - 09/2012
2	Acute-Phase Proteins (Acute-Phase Protein)IBA 06/2020 - 08/2014
2	VimentinIBA 01/2020 - 04/2011

Therapy/Procedure

17	Therapeutics 04/2022 - 10/2006
6	Neoadjuvant Therapy 01/2022 - 06/2018
5	Drug Therapy (Chemotherapy) 01/2022 - 01/2013
3	Adjuvant Chemotherapy 09/2022 - 01/2016
3	Radiotherapy 10/2020 - 04/2018